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care health plan; patientswere followed until death, disenrollment from the health
plan, or 12/31/2008. Health care costs in the 24 months prior to death/end of fol-
low-up were calculated, divided into 4-month periods to assess trends over time.
Chi-square statistics were used to compare patients who died vs. those alive at the
end of the study on health care costs, comorbidity, clinical, and demographic
characteristics. RESULTS: 260 CRPC patients died, with 2304 patients alive at the
end of the study (mean age 73.99 vs. 72.63 years, p0.035). 2 years prior to death/
end of follow-up, comorbidity scores were similar and mean total costs per
4-month period were not significantly different for patients who died vs. those
alive ($8,292 vs. $6,809, p0.060). Health care costs increased prior to death, with
the sharpest increase in the last 4-months of life with mean costs roughly tripling
(from $15,185 to $44,203). For patients who did not die, mean total costs increased
by one-third in each 4-month period, from$6,809 to $13,170 at the end of follow-up.
CONCLUSIONS: Although costs were initially similar for CRPC patients who died
compared to patients alive at study end, patients who died had significantly larger
increases in costs over the 2-year period, with the sharpest increase in the last year
prior to death.
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OBJECTIVES: 7,538 new cases of SCCHN were diagnosed in 2006 and 2,594 deaths
reported in 2007 in the UK. For patients with resectable SCCHN surgical resection
followed by postoperative radiation therapy remains a common treatment ap-
proach. For locoregional disease control chemotherapy is also an important treat-
ment component. METHODS: This retrospective analysis was based on inpatient
and outpatient records extracted from Hospital Episode Statistic database. SCCHN
patients with resection of oral cavity, pharynx or larynx between 2003-07-01 and
2008-03-31 were followed for at least one year (max. of 5 years) from the surgery
date. RESULTS: There were 38,460 patients diagnosed with SCCHN in the dataset.
11,403 patients met the inclusion criteria for the study. Mean age was 63.2 years
and 69.8% were male. Mean length of follow-up was 31.0 months. In the first year,
mean length of hospitalizationwas 21.6 days andmeannumber of outpatient visits
was 4.2. Mean number of reconstructive and secondary surgeries per patient was
0.32 and 0.14, respectively in the first year. Mean number of radiotherapy and
chemotherapy sessions per patient was both 0.45 in the first year. Total costs of
post-operative healthcare utilization in the patient cohort was £249.4 million over
5 years with 90% (£225.5 million) occurring within the first year. Mean cost was
£19,778 for the first year and £1477, £847, £653 and £455 for years 2-5. Inpatient care
costs accounted for 96% of total costs with hospitalization contributing to 85% of
these costs.CONCLUSIONS:Given limited outpatient data in theHES, radiotherapy
and chemotherapy utilization and costs in the outpatient setting are likely to be
underestimated. However, results still indicate that treatment of resected SCCHN
in the UK is associated with significant healthcare utilization and costs. This sug-
gests the need for new therapies that could improve outcomes and reduce the
economic burden.
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OBJECTIVES: Out-of-pocket (OOP) medical expenditures of families may pose a
financial burden, particularly to the seriously ill. The objective of this study was to
analyze financial burden among patients with three common cancers: breast can-
cer (BC), colorectal cancer (CRC), and lung cancer (LC). METHODS: This study in-
cluded respondents in the US Medical Expenditure Panel Survey who had 1 BC
(ICD-9-CM 174.xx), CRC (ICD-9-CM 153.xx, 154.xx), or LC (ICD-9-CM 162.xx) diagno-
sis between 1996 and 2007. Matched comparison cohorts (without cancer) were
constructed for each cancer type, based on age, payor, sex, race and region. All
years of datawere pooled andweighted to create nationally representative average
annual estimates reported in 2009 USD. OOP family medical expenditures (not
including premiums), and family income were analyzed. Families were defined as
having a highOOP burden if their OOP expenditures exceeded 10% of annual family
income (5% if low income). RESULTS: 1,849 patients with cancer were identified
(1,083 BC, 467 CRC, 299 LC). Total OOP expenditures averaged $3,400 - $4,400 for
cancer patients versus $2,100 - $2,700 for controls. Overall, 31-37% of cancer pa-
tients had high OOP burden (31% BC, 37% CRC, 35% LC), compared to about a
quarter of matched comparison patients. Among those under age 65, 16-30% of
privately insured hadhigh burden. Among those 65,moreMedicare-only patients
had high burden (48-53%) compared to those with Medicare plus other insurance
(29-36%). CONCLUSIONS: Over a third of cancer patients have OOP expenditures
greater than 5-10% of their household income. Privately insured patients appear
least likely to have high burden while publicly insured appear most likely. To
ensure that cancer patients can adequately access needed medical care, explora-
tion of how US health reform or other policy options could reduce this financial
burden is warranted.
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OBJECTIVES:Monoclonal antibodies improve treatment outcomes in patients with
metastatic colorectal cancer (mCRC); they have distinct and known safety profiles
that may be associated with toxicities requiring hospitalization, which likely fur-
ther impact cost of patient care. The objective of this study was to determine
hospital costs of these events.METHODS: From the PHARMO Record Linkage Sys-
tem, including drug dispensing and hospitalization records of approximately 3.2
million residents in The Netherlands, all patients with a primary or secondary
hospital discharge code for CRC and distant metastasis between 2000 and 2008
were defined as patients with mCRC. The first discharge diagnosis defining metas-
tases served as the index date. Patients were followed from index date until end of
data collection, death, or end of study period, whichever occurred first. Main out-
comes for each identified event were length of stay (days) and costs per hospital
admission (€). All results are presented descriptively. RESULTS: Among 2,964 pa-
tients with mCRC identified, 271 hospital events occurred during a median fol-
low-up of 24 months. The longest mean ( SD) lengths of stay per hospital admis-
sion were for stroke (16 ( 33) days) and arterial thromboembolism (ATE) (14 ( 21)
days), followed by wound healing complications (WHC), acute myocardial infarc-
tion (AMI), congestive heart failure (CHF), and neutropenia (all 9 days with SD 5 to
15). Highest mean ( SD) costs per admission were observed for stroke (€13,500 (
€28,800)), ATE (€13,300 ( €18,800)), andWHC (€10,800 ( €20,500)), followed by AMI
((€9,000 ( €7,300)), neutropenia (€7,900 ( €4,400)), and CHF (€7,700 ( €6,300)).
Lowest mean ( SD) costs were for dermatological toxicity (€5,400 ( €5,200)) and
hypertension (€4,100 ( €2,800)). CONCLUSIONS: Inpatient costs for events in pa-
tients with mCRC are considerable and vary greatly. Such data are valuable to the
pharmacoeconomic evaluations of newer treatments in patients with mCRC.
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OBJECTIVES:To study themedical expenditure of insured patientswith cancer and
its influence factors, to analyze the utilization of pharmaceuticals, treatment-seek-
ing behavior and the relationship between the medical expenditure and payment
patterns ofmedical insurance.METHODS:This study involved 5351 cancer cases in
3 municipalities (Beijing, Shanghai, Chongqing) and 5 province-capital cities (She-
nyang, Fuzhou, Jinan,Zhengzhou, Xining).The actual claim data of their medical
expenditure and medical care utilization in 2008 were collected. Descriptive anal-
ysis and multivariate linear regression analysis were applied. RESULTS: 1) Outpa-
tient’s annual medical expenditure per head was US$802 and inpatient’s annual
medical expenditure per head was US$6200. Although the basic medical insurance
(BMI) fund covered about 70% of the expenditure, the patients’ economic burden is
still heavy. 2) Western medicine cost accounted for 44% to 60% of the inpatients’
medical expenditure in various cities. Cytotoxic drug usage accounted for over 80%
of the anti-tumor drugs. 3) The proportion of the patients who sought outpatient
and inpatient treatment in the third level hospitals was 81% and 74%, respectively.
4) Multivariate linear regression analysis showed that themain influence factors of
inpatients’ medical expenditure include medical insurance payment pattern, hos-
pital level, category of cancer, gender, length of stay in hospital, and medical in-
surance type. When all factors other than payment pattern were set to be control
parameters, inpatient’s annual medical expenditure per head under flat rate pay-
ment was US$348 lower than that under fee-for service. CONCLUSIONS: Medical
expenditure causes heavy burden for cancer patients and the BMI fund. Flat rate
payment has proved to be more effective in expenditure control compared with
fee-for service. To keep the fund safe and running effectively, it is necessary to
adjust present payment patterns and set rational payment standard to encourage
medical care providers to control the expenditure actively.
PCN46
HEALTH CARE EXPENDITURES, DISABILITY DAYS, AND RESOURCE
UTILIZATION ASSOCIATED WITH CANCER IN EMPLOYER SETTINGS IN THE
UNITED STATES
Tang D1, Alberts DS1, Nevins R2, Sullivan S2, Skrepnek GH1
1The University of Arizona, Tucson, AZ, USA, 2Institute for Health and Productivity
Management, Scottsdale, AZ, USA
OBJECTIVES: To assess healthcare expenditures, disability days, and resource uti-
lization in persons with cancer that were employed within large and small organi-
zations in the United States. METHODS: This retrospective database analysis uti-
lized 2007 Agency for Healthcare Research and Quality (AHRQ) Medical
Expenditure Panel Survey (MEPS) public-use data. Inclusion criteria included age
18 years, any diagnosis of malignant neoplasms (including both new cases and
those continuing treatment), and employment within either large or small organi-
zations (500 or 500 employees, respectively). Regression analyses were per-
formed via gamma or negative binomial generalized linearmodels for outcomes of
total direct healthcare expenditures, number of disability days, and summed re-
source utilization (outpatient visits, emergency department visits, hospitaliza-
tions) after controlling for predominant cancer types and other factors including
demographics (age, sex, race, education, region, income, residence), insurance cov-
erage, employer size, perceived health status, secondary malignancies, and the
D’Hoore-Charlson Comorbidity Index. To provide national estimates, all results
were weighted and used standard errors (SE) calculated via Taylor-series
approaches. RESULTS: Overall, 3.86 million employed adults in the US had new or
continued cases of cancer in 2007, averaging 54.0 (SE0.9) years of age, 9.3 (SE1.8)
disability days, and $15,365 (SE2921) in expenditures. Mostwere employedwithin
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small organizations (84.0%, n3,243,961). Regression analyses indicated that in-
creased expenditures were associated with large organizations (exp(b)2.00,
p0.025) andprostate cancer (exp(b)1.88, p0.039). Increased disability dayswere
associated with melanoma (exp(b)3.57, p0.039) and cancer of the uterus
(exp(b)4.90, p0.006). Higher resource utilization was associated with breast can-
cer (exp(b)1.76, p0.011) and cancer of the uterus (exp(b)1.85, p0.025).
CONCLUSIONS:Cancer is associatedwith a substantial burden in theworkplace, as
3.86 million persons were diagnosed with new cases or had continued treatment
while being employed in large or small organizations in 2007. Healthcare expendi-
tures summed to $59.3 billion, while 35.8 million total disability days were in-
curred.
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OBJECTIVES: Acute lymphocytic leukemia (ALL) is most common in children. Due
to advances in therapy options, the number of long term survivors of pediatric ALL
continues to increase. However, although prognosis has improved significantly
over time, ALL likely continues to impose a significant economic burden on society.
This study sought to assess recent trends in pediatric ALL hospitalization and
aspects of related care. METHODS: Data for pediatric (20 years) hospitalizations
with a primary diagnosis of ALL (ICD-9-CM codes 204.0x) from the 1997, 2000, 2003,
and 2006 HCUP Kids’ Inpatient Databases were analyzed. Weighted estimates of
the number of hospitalizations for ALL and associated resource-based outcomes
(i.e., total charges, length of stay [LOS], and stem cell transplant procedures) were
derived. RESULTS: Between 1997 and 2006, the rate of pediatric ALL-related hospi-
talizations (per 100,000 2010 US pediatric population) increased slightly then lev-
eled off, from 6.10/100,000 in 1997 to 6.61/100,000 in 2000, 6.60/100,000 in 2003, and
6.62/100,000 in 2006. Mean LOS remained consistent until an increase in 2006 (12.1
days in 1997, 12.4 days in 2000 and 2003, to 13.6 days in 2006). Similarly, the pro-
portion of ALL hospitalizations with evidence of stem cell transplant remained
roughly unchanged at 60% until a sharp increase in 2006 to 64.9%. Finally, mean
costs (2010 USD) for ALL-related stays have increased nearly 31%, from $43,247
(1997) to $56,517 (2006). CONCLUSIONS: We examined rates of pediatric ALL-re-
lated hospitalizations and documented aspects of inpatient ALL care, and observed
a slight increase in the rate of hospitalizations over time. An increase in LOS was
seen in 2006, with a commensurate increase in total costs, possibly owing to a
marked increase in the rate of stem cell transplant. These findings may be used to
support access strategies (e.g., economic modeling efforts) for current ALL thera-
pies, as well as for those in the developmental stage.
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OBJECTIVES: To assess the average total daily CINV-related hospital outpatient
visit cost (CINV-OC) among patients with cancer treated with any chemotherapy
(CT) and initiated on anti-emetic prophylaxiswith palonosetron versus other 5-HT3
receptor antagonists (5-HT3 RAs) in a hospital outpatient setting. METHODS: Pa-
tients with a cancer diagnosis initiating CT and palonosetron (Group 1) and other
5-HT3-RAs (Group 2) for the first time (index date) between April 1, 2007-March 31,
2009 were identified from the Premier Perspective database. Key inclusion criteria
were patients aged  18 years and no nausea and/or vomiting and CT and anti-
emetic medication use in the 6-month pre-index date period. A multivariate GLM
model estimating the average daily CINV-OC in the follow up period (first of eight
CT cycles or sixmonths post-index date) was developed after adjusting for baseline
differences in several demographic and clinical variables. RESULTS: Of 9,144 iden-
tified patients, 1,775 (19.4%) initiated palonosetron. Versus group 2 patients, group
1 patients were significantly younger [61.2 (SD: 13.0) vs. 62.8 (13.1) years; p0.0001],
comprised more females [52.5% vs. 41.1%; p0.0001], less African American pa-
tients [8.6% vs. 13.2%; p0.0001] and more Hispanic patients [6.0% vs. 4.1%;
p0.0001], and a lower percent of patients received LEC and MinEC combined
(14.3% vs. 31.8%; p0.0001). In the follow-up period, unadjusted average daily
CINV-OC among group 1 patients was significantly lower versus group 2 patients
[$1,047.9 (SD: $1,444.5) vs. $1,339.1 (SD: $2,040.0); p0.0014]. After controlling for
potential confounders, the regression model predicted a 12.0% decrease in the
average CINV-OC; p0.0076 in favor of group 1 patients versus group 2 patients.
CONCLUSIONS: In this retrospective hospital outpatient study, patients with can-
cer treated with CT and initiated on palonosetron anti-emetic prophylaxis were
more likely to experience a significantly lower average daily CINV-OC versus those
initiated with other 5-HT3-RAs.
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OBJECTIVES: The major aims of the current research are to learn the average cost
of treatment of Chronic lymphocytic leukemia (CLL) in Ukraine and examine fac-
tors that may be associated with it. The number of patients burdened by the dis-
ease in Ukraine is considerable and cost implications for individuals requiring care
are significant. In Ukraine only limited amounts of necessary medicines are com-
pensated by the government, with the major expenses covered by patients
themselves. METHODS: A database containing records from hospital cards (2004-
2010) for patients with CLL was analyzed retrospectively. The sample was com-
posed of 113 patients, aged 39 to 85 (mean age 61.3, 61.9% males). Medicine costs
related only to direct diagnosis were calculated. RESULTS: The average annual
costs of pharmaceutical treatment for patient with relapse were $1,561.16 (1$7.95
UAH on 12.01.2011). A negative correlation was found to exist between age of the
patient’s diagnosis and costs of treatment (r.218; p .05). Furthermore, similar
to past research in other countries male gender was associated with a significant
increase in treatment costs, t(109)1.95, p.05. CONCLUSIONS: Although other
studies on CLL have shown a positive association between treatment cost and age,
our research showed an opposite association for the sample studied in Ukraine. A
possible explanation can be income limitations among the elderly thatmay restrict
their ability to pay for medicines and, simultaneously, cause doctors to prescribe
lower-priced pharmaceuticals. The average annual cost of treatment for CLL is
higher than the minimum subsistence level, equal to $1,320.75 for people of work-
ing age and $1,107.92 for the retired population. To ensure effective treatment,
especially for vulnerable populations, reimbursement for pharmaceuticals should
be implemented.
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OBJECTIVES: In Hungary, costs of anti-cancer protocols are covered by hospitals’
budget, and the funds of therapy expenditures provided by DRG accounts, on
a”cycle-by cycle” basis. Main goal of research was to investigate the cost of medi-
cines of colon cancer chemotherapies and compare to DRG based remittance allo-
cated by National Health Fund. METHODS: Cost analysis of CRC chemotherapy
protocols has been conducted from the perspective of audited Oncology Centres.
Regimens of 5-fluorouracil, raltitrexed, capecitabine, irinotecan, cetuximab, bev-
acizumab and oxaliplatin have been investigated, focusing on cost of medication,
and DRG value of protocols. Research time horizon was January-June 2010.
RESULTS: Real expenditures of protocols were assessed. The range of drug related
costs were 3.1-3412.9 USD as expenditures of hospitals. Total expenditures of che-
motherapy-regimens have been assessed and compared to allocation of remit-
tances from National Health Fund Administration. The value of remittances have
been found between 303.7 and 3261.8 USD, depending on protocols. The analysis of
drug expenditures and remittances has resulted a wide range of gap:- 178.0 to
1167.5 USD. The ratio of drug related expenditures and total remittance of hospitals
showed diversity from 1.0% to 125.1%. CONCLUSIONS: As demonstrated by the
analysis of costs, one of the reasons of the increase in expenditures spent on the
therapy of metastatic colon cancer is the emerging of these new, expensive high effi-
ciency therapies. Analysis showes, that fixed DRG values does not represent expendi-
ture of chemotherapies of CRC treatment. Neihter priority, nor incentive elements
have been found in protocols, containing molecules with high efficacy or improved
safety. Remittances should be validated regulary, based on hospitals’ perspective.
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OBJECTIVES: Consultation planning (CP), a decision support service for patients
provided by trained lay people, increases cancer patient’s decision-self-efficacy
(DSE) when conducted in-person. It may be more cost-beneficial to conduct CP by
telephone. Compare DSE, costs, willingness-to-pay (WTP) and cost-benefit (CBA) of
two CP delivery methods in rural breast cancer patients. METHODS: Randomly
assigned clients from cancer resource centers were enrolled (n67). Interventions
were CP in-person (n32) or by telephone (n35) between patients and trained
resource center staff to discuss knowledge for informed care decisions at their next
physician visit. Outcomeswere DSE andWTP for services. 2009 costs of training, CP
and patient time, travel, telephone, and center overhead were determined. We
compared costs and WTP using t-tests, ranked-sum or Kolmogorov-Smirnov tests
depending on Shapiro-Wilk tests for normality. CBA compared net benefit and CB
ratios for deliverymethods. RESULTS:As hypothesized, DSE did not differ between
deliverymethods (mean3.44 in-person;3.54 telephone) but each improved signif-
icantly (p0.001). Patients’ WTP did not differ by method; telephone ($154), in-
person ($144) (p0.78). Intervention costs were significantly lower for telephone
than in-person ($139 vs $181,p0.001) due to higher patient travel for in-person
($26 vs $2,p0.001). Training costs were $5.78-$147/person depending on amorti-
zation volume. Net benefit for telephone over in-person is $52; $42 less cost, with
$10 more value. CB ratios when training ($6.00-$147/patient) and overhead ($25/
patient) are added to program costs are 0.41-0.68 for in-person and 0.49-0.90 for
telephone depending on number delivered, so patients are WTP up to 68% of in-
person and 90% of telephone costs; 22% more return-on-investment for telephone
CP. CONCLUSIONS: Telephone delivery is more cost-beneficial than in-person CP.
The value of CP is the same for eithermethod and there are significant cost savings
with telephone delivery. Adoption of CP by telephone could result in additional
access for rural patients.
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